Literature DB >> 16545460

Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation.

C Graf, G Gavazzi.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16545460     DOI： 10.1016/j.jinf.2006.01.019

Source DB:  PubMed          Journal:  J Infect        ISSN： 0163-4453            Impact factor:   6.072


× No keyword cloud information.
  6 in total

Review 1.  Probiotics in clostridium difficile Infection.

Authors:  Xi Na; Ciaran Kelly
Journal:  J Clin Gastroenterol       Date:  2011-11       Impact factor: 3.062

Review 2.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183

3.  Overview of Clostridium difficile infection: implications for China.

Authors:  Xinhua Chen; J Thomas Lamont
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-11-04

4.  Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii.

Authors:  Indu Khatri; Rajul Tomar; K Ganesan; G S Prasad; Srikrishna Subramanian
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

5.  Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients.

Authors:  Beata Sulik-Tyszka; Emilian Snarski; Magda Niedźwiedzka; Małgorzata Augustyniak; Thorvald Nilsen Myhre; Anna Kacprzyk; Ewa Swoboda-Kopeć; Marta Roszkowska; Jadwiga Dwilewicz-Trojaczek; Wiesław Wiktor Jędrzejczak; Marta Wróblewska
Journal:  Probiotics Antimicrob Proteins       Date:  2018-06       Impact factor: 4.609

6.  Transcriptomics in human blood incubation reveals the importance of oxidative stress response in Saccharomyces cerevisiae clinical strains.

Authors:  Silvia Llopis; Amparo Querol; Antje Heyken; Bernhard Hube; Lene Jespersen; M Teresa Fernández-Espinar; Roberto Pérez-Torrado
Journal:  BMC Genomics       Date:  2012-08-23       Impact factor: 3.969
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.